Trump’s Medicare GLP-1 drug plan to cost insurers ‘billions,’ Bloomberg reports

A new analysis suggests President Donald Trump’s proposal to expand Medicare coverage for weight-loss GLP-1 drugs could cost health insurers billions in the first year, Bloomberg’s Rachel Cohrs Zhang reports. While the administration argues negotiated lower drug prices would offset the expense and avoid burdening taxpayers, the findings raise concerns about the near-term financial impact of broadening access, the report says. Publicly traded companies in the insurer space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH), while public companies making GLP-1 drugs include Novo Nordisk (NVO) and Eli Lilly (LLY).